NCT03925987

Predicting Treatment Response to Exposure Therapy Using Carbon Dioxide

Completed NA Last updated 15 December 2023

What this trial tests

NA trial testing Exposure therapy in Generalized Anxiety Disorder in 70 participants. Completed in 31 July 2020.

Timeline

7 June 2018

Primary endpoint
31 January 2020

31 July 2020

Quick facts

Lead sponsor	Laureate Institute for Brain Research, Inc.
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	basic science
Enrollment	70
Start date	7 June 2018
Primary completion	31 January 2020
Estimated completion	31 July 2020
Sites	1 location across United States

Drugs / interventions tested

• Exposure therapy

Conditions studied

• Generalized Anxiety Disorder — all drugs for Generalized Anxiety Disorder →
• Social Anxiety Disorder — all drugs for Social Anxiety Disorder →
• Panic Disorder — all drugs for Panic Disorder →
• Agoraphobia — all drugs for Agoraphobia →

Sponsor

Laureate Institute for Brain Research, Inc.

Who can join

Adults 18 to 55, any sex, with Generalized Anxiety Disorder or Social Anxiety Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Anxiety disorders affect over a quarter of the population, yet very little is known about the variables that predict treatment outcome. The planned study explores whether a patient's response to a physiological test involving inhalation of carbon dioxide predicts their response to exposure therapy.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. ACNP 58^th Annual Meeting: Poster Session III.
   · 2019 · cited 2× · PMID 31801974 · DOI 10.1038/s41386-019-0547-9